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Abstract
Background: Recent outbreaks of canine distemper have prompted examination of strains from clinical samples
submitted to the University of Tennessee College of Veterinary Medicine (UTCVM) Clinical Virology Lab. We previously
described a new strain of CDV that significantly diverged from all genotypes reported to date including America 2, the
genotype proposed to be the main lineage currently circulating in the US. The aim of this study was to determine when
this new strain appeared and how widespread it is in animal populations, given that it has also been detected in fully
vaccinated adult dogs. Additionally, we sequenced complete viral genomes to characterize the strain and
determine if variation is confined to known variable regions of the genome or if the changes are also present
in more conserved regions.
Methods: Archived clinical samples were genotyped using real-time RT-PCR amplification and sequencing. The
genomes of two unrelated viruses from a dog and fox each from a different state were sequenced and aligned with
previously published genomes. Phylogenetic analysis was performed using coding, non-coding and genome-length
sequences. Virus neutralization assays were used to evaluate potential antigenic differences between this strain and a
vaccine strain and mixed ANOVA test was used to compare the titers.
Results: Genotyping revealed this strain first appeared in 2011 and was detected in dogs from multiple states in the
Southeast region of the United States. It was the main strain detected among the clinical samples that were typed from
2011–2013, including wildlife submissions. Genome sequencing demonstrated that it is highly conserved within a new
lineage and preliminary serologic testing showed significant differences in neutralizing antibody titers between this
strain and the strain commonly used in vaccines.
Conclusion: This new strain represents an emerging CDV in domestic dogs in the US, may be associated with a stable
reservoir in the wildlife population, and could facilitate vaccine escape.
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Background
Canine distemper virus (CDV) is an enveloped negative-
sense, single-stranded RNA virus that produces multi-
systemic disease in dogs and other terrestrial carnivores
[1]. Similar to measles virus, CDV is a member of the
genus Morbillivirus within the family Paramyxoviridae.
The virus is highly contagious and results in immuno-
suppression in the host. Clinical signs associated with in-
fection may include gastrointestinal signs (vomiting and
diarrhea) and/or respiratory signs that may be compli-
cated by secondary bacterial infection (purulent nasal
discharge, coughing, dyspnea, pneumonia). The infection
may progress to the central nervous system (CNS) and
may result in death.
Despite extensive vaccination of dogs in developed
countries, recent reports suggest both re-emergence and
increased activity of CDV worldwide, including the
United States [2–6]. We have seen an increase in overall
CDV positive samples submitted to University of
Tennessee College of Veterinary Medicine (UTCVM) Clin-
ical Virology Lab from 5 % in 2010 to 27 % in 2013 [7].
Traditionally, circulating field strains cluster into
distinct clades. These distinct genotypes have been des-
ignated as genetic lineages and named based on the geo-
graphic regions where the genotypes were originally
detected [2–4, 6]. While there have only been two North
American lineages clearly defined, recent reports suggest
at least 3 lineages (including 2 newly identified genotypes)
are circulating in South America [3]. We previously
sequenced regions from CDV positive samples and based
on limited phylogenetic evaluation there appear to be 3–4
different “North American” genotypes currently circulat-
ing in the USA, including a new genotype of CDV we
discovered circulating in Tennessee [7].
Most currently circulating strains are genetically diver-
gent from the strains used for vaccine production.
Onderstepoort and Snyder Hill strains (designated
America 1 lineage) were used for vaccine production in
the 1950s, and the vaccines have not changed since then
[8, 9]. Many have questioned the efficacy of these vac-
cines with reports of CDV in previously vaccinated dogs
since the 1990s [10], including recent reports in Japan
[11], Mexico [12], Argentina [13], and the United States
[5]. There are multiple reasons vaccines may fail aside
from genetic differences, such as interference of mater-
nal antibody resulting in incomplete protection and
improper handling of the vaccine [1]. However, as newly
emerging strains with significant genetic diversity from
the available vaccine strains are detected, changes in
virulence as well as antigenicity are anticipated in light
of previously reported vaccine breakthroughs.
One aim of this present study was to evaluate additional
archived samples to determine when this new strain first
appeared, its geographic distribution, and if it is associated
with the perceived increase in CDV cases from 2011 to
2013 and continuing into 2014. We then sought to investi-
gate if this strain is conserved utilizing genome sequen-
cing and phylogenetic analysis of two samples obtained
from independent geographic regions, points in time and
different species. We also performed initial serologic test-
ing to evaluate presence of antigenic variation compared
to a commonly used vaccine strain Onderstepoort. This
type of information is necessary for future efforts toward
determining vaccine efficacy.
Results
Eighty-four of 352 samples tested from 2011 to 2013 were
positive for CDV by real-time RT-PCR. Only one sample
from each of 3 independent outbreaks in shelters and a
pet store is included in these numbers, so the numbers ac-
tually do not reflect the total number of samples tested or
the total number of positive samples. This was done to
demonstrate that these positive samples were not just
associated with isolated outbreaks. The majority of these
samples were submitted from client-owned, young adult
dogs from individual homes. Vaccination history was
missing for several dogs, but most of the animals were
unvaccinated or only partially vaccinated. Three adult
dogs (ages 1, 4, and 8 years old) with complete vaccination
histories were positive for CDV. Based on veterinary re-
cords, these dogs had been properly vaccinated according
to vaccine guidelines and one of the dogs (8 year old) had
actually been vaccinated yearly, rather than the recom-
mended every three years schedule.
Genotypes of 22 wild-type strains were previously re-
ported [7] and are included in the numbers reported
here for completeness. An additional 33 positive samples
were typed for this report, including 5 samples from
2014. Genotyping of samples obtained from different
geographic regions and different states revealed this new
strain as the predominant strain from the majority of
samples typed from 2011 to 2013 (75 % of the samples
from 2011(3/4); 73 % from 2012(11/15); 86 % (24/28) of
the samples from 2013), but it was not detected in sam-
ples collected in 2010 (0/5). This strain was detected in
35/39 samples typed from eastern Tennessee (between
2011 and 2013), including every county tested (10 differ-
ent counties), and it was still circulating in Tennessee in
2014 (2/5). We also detected this novel strain in 1/3
samples typed from Virginia, 1/1 from South Carolina,
and 1/1 from West Virginia. This strain was not detected
in a limited number of samples from Canada, Washing-
ton, Texas, or Kentucky. These genotyping results using a
portion of the M gene and the M-F region and compared
to other published sequences are displayed as a phylogen-
etic tree (Fig. 1).
Both CDV 13–1941 and 13–2262 were sequenced to
near completion including all coding sequence and
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intergenic space and sequences were deposited [GenBank:
KJ747371 and KJ747372], respectively. Reference complete
or near-complete genomes from GenBank were aligned to
our two sequences and used to develop a phylogenetic
tree (Fig. 2). Hemagglutinin (H) gene sequences from
these samples were aligned with H gene sequences in
GenBank and were also used to develop a phylogenetic
tree (Fig. 3). Phylogenetic trees based on individually
extracted protein sequences for 6 genes (N, P, M, F, H, L)
in the genome displayed similar relationships to the whole
genome analysis and thus were not included in this manu-
script. CDV 13–1941 and CDV 13–2262 outgroup in rela-
tion to the other genome sequences and form a distinct
clade with extremely limited heterogeneity. A comparison
Fig. 1 Phylogenetic tree comparing relatedness between M-F region of various CDV strains. The new strain described in this study represents a novel
distinct clade significantly divergent from all previous sequences (lower branch). We also identified some sequences that match previously existing
clades. Isolates used for genome sequencing are in bold, and their placement among the other isolates suggests that genome-level conservation is
likely present in all isolates of the “new” strain. Consensus unrooted phylogenetic trees were generated within Geneious© using the Tamura-Nei model
with UPGMA clustering and 1000 bootstrap replicates
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of amino acid differences among hemagglutinin genes
(commonly used to investigate phylogenetic relationships
and evolution of CDV) [3] from different lineages
supports this relationship (Table 1).
In addition to strong sequence conservation in the new
genotype, genome sequencing revealed an alternate start
codon for both sequences (13–1941 and 13–2262) of the
fusion (F) protein, adding 75 nucleic acids (25 amino
acids) to the signal peptide region relative to its closest
relatives on the phylogenetic tree (Fig. 4). Evaluation of
the hemagglutinin protein showed this strain has 7 poten-
tial N-glycosylation sites (N149, N309, N391, N422, N456,
N587, N603). It lacks the site at N584 that has been found
in some Asian strains [14].
Serum obtained from 5 adult dogs prior to and follow-
ing a yearly booster vaccination with a modified-live
CDV vaccine showed statistical differences in serum
neutralization titers when the vaccine strain virus was
used in testing versus a clinical isolate of the new strain.
Pre-vaccination geometric mean titers for the vaccine
strain and the new genotype were 42.09 (low titer 32,
high 128) and 21.11 (low titer 8, high 32), respectively.
Post-vaccination geometric mean titers for the vaccine
strain and the new strain were 240.37 (low titer 128,
high 512) and 52.05 (low titer 8, high 64), respectively.
There was a statistically significant difference (p = 0.05)
between titers pre- and post- vaccination against the
vaccine strain but not between titers pre- and post-
vaccination against the new strain. There was a statistically
significant difference (p = 0.05) between the titers both
pre-vaccination and post-vaccination when comparing the
titers between the two viruses (Fig. 5).
Discussion
This new strain of CDV is highly conserved over the
period of surveillance, geographic region and host spe-
cies. It appears to be widespread in the Southeast US,
but samples evaluated were samples of convenience
(those submitted to the diagnostic lab for CDV testing).
Additional states are likely involved but more samples
are required from both healthy and symptomatic animals
for an epidemiological survey.
Unlike a previous report that suggests strains stemming
from the America-2 lineage are the dominant “American”
Fig. 2 Phylogenetic tree for genome sequences representing major geographic regions. Two genomes sequenced from the new strain (bold) diverge
significantly from other sequenced genomes. The distance between the new strain is similar to the distance between recognized geographically distinct
strains, as well as vaccine strains. Tree was constructed using MrBayes (Bayesian inference) using the GTR substitution model with 1,000,000 iterations and
subsampling every 1000 trees
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strain in circulation [15], at least in eastern Tennessee, this
new strain was predominant in 2011–2013. We consider
this to be the third “contemporary” genotype that has
been detected in North America.
The first contemporary genotype described was America
2 (represented by red clade, Fig. 3). The term genotype
has been used in the grouping of CDVs, but a formal ana-
lysis has yet to be published. Genotypes have been defined
by the phylogenetic properties of the H-gene amino acid
sequence. Strains in the same clade showing more than
95 % amino acid homology are considered to belong to
the same genotype [14]. This is an arbitrary distinction,
and depending on which sequences are used for compari-
son the 95 % difference does not always hold true when
considering currently recognized genotypes. This is evi-
dent when comparing one of the European strains
(GenBank Accession DQ494319) with a European Wild-
life strain (GenBank Accession (DQ228166) versus the
same comparison when using a different European strain
(GenBank Accession Z47761) (Table 1).
We performed phylogenetic evaluation of current US
strains in comparison to our strains and discovered circula-
tion of another clade that has already been described but
not well-defined in the literature (yellow clade, Fig. 3). A
virus belonging to this clade was initially detected by Pardo
et al. in 2005 [16], sample 19876 (GenBank accession
AY964110), detected in Missouri, USA in 2004 but was not
defined as a new genotype at that time. Strains belonging to
the clade represented by sample 19876 were also detected
by additional researchers and suggested to be part of the
European Wildlife lineage [5] or a subgroup thereof [17]
(CDV outbreak in fishers in California (GenBank accession
numbers JN836734-7), based on partial H gene sequencing.
Strains grouping with the 19876 clade were later also
Fig. 3 Phylogenetic tree for H gene. H gene tree also displays this
new strain of CDV as a separate clade (blue) from previously identified
genotypes, including the America 2 genotype (red clade). Based on H
gene sequence analysis, there are at least three separate “American”
clades of CDV currently circulating in the U.S
Table 1 H gene divergence/percent identity
AS2 88.74
EU/SAM1 89.24 92.26
AFRICA 89.90 93.08 94.23
AS1 89.40 93.25 92.75 93.57
13_1941 89.40 92.74 93.40 93.40 93.56
13_2262 89.40 92.75 93.41 93.41 93.57 99.67
SAM3 89.07 92.26 91.93 92.75 92.59 93.56 93.57
EW 90.07 93.09 93.25 93.75 93.58 94.56 94.57 93.42
19876 90.23 93.25 93.57 94.23 94.07 94.55 94.56 93.90 94.41
SAM2 89.74 92.26 92.92 93.25 93.41 94.22 94.23 93.25 94.41 94.40
AM2 90.89 93.41 94.07 94.73 95.06 95.05 95.06 94.73 95.39 95.39 95.22
EU 90.73 93.90 94.23 94.40 95.06 95.21 95.22 95.22 95.56 95.72 96.05 96.87
AM1 AS2 EU/SAM1 AFRICA AS1 13_1941 13_2262 SAM3 EW 19876 SAM2 AM2
GenBank numbers: AF378705 (AM1, America 1); Z54166 (AM2, America 2); AB687720 (AS1, Asia 1); AB474397 (AS2, Asia 2); DQ228166 (EW, European Wildlife);
FJ461723 (AFRICA); KC966929 (ARCTIC); DQ494319 (EU, Europe); Z47761 (EU/SAM1, Europe/South America 1); FJ392651 (SAM 2, South America 2); KF835420
(SAM3, South America 3); AY964110 (19876- USA)
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detected in Mexico (Edomex strains) and the researchers
defined the clade as a new genotype/lineage [4]. Based on
our phylogenetic analysis, we concur the clade represented
by sample 19876 should be recognized as a new genotype
based on H gene divergence (Table 1) and viruses from this
genotype are currently circulating in Tennessee and Texas
in the US.). Therefore, in staying with the current genotype
naming scheme, this clade represents America 3 (yellow
clade, Fig. 3).
Based on clade groupings and hemagglutinin amino acid
divergence, we suggest this new strain circulating in the
Southeast also represents a new genotype and should be
called America 4 (blue clade, Fig. 3). This new America 4
genotype outgroups from other clades with similar dis-
tances as each previously described genotype does from
each other. SNPs between the clades outnumber SNPs
within each clade, yet CDV 13–1941 and 13–2262 have
fewer differences between them than all but clonally de-
rived isolates (only 56 nucleotide differences across the
two genomes). This is unexpected as these two samples
came from different species of animals, at different times
and in different location with no obvious route of com-
mon exposure or transmission. It is also highly conserved,
supporting the hypothesis that this novel lineage is most
likely contained in a stable host reservoir with break-
through transmission to other species.
In addition to the sequence divergence from other clades,
an alternate start site increasing the size of the signal pep-
tide of the F protein has been previously reported in the
Asia-2 lineage [6]; however, this new strain adds 9 add-
itional amino acids even beyond the Asia-2 variant. It has
been suggested that variations in the signal peptide region
affect F protein expression and a longer signal peptide re-
gion might result in reduced F protein production and per-
sistent infection due to evasion of the immune system [18,
19]. This observation, in addition to the highly conserved
genome, fits with our hypothesis that this strain is represen-
tative of a stable reservoir. Figure 1 reveals that the hyper-
variable M-F region is practically identical, if not
completely identical in most of the isolates typed as the
new strain. This means that the two genomes we se-
quenced are unlikely to be coincidentally conserved and
the other isolates are, in all probability, equally conserved at
the genomic level.
A virus capable of infecting and transmitting in wild-
life yet not causing severe disease in a large number of
infected animals would be under less selective pressure
and show reduced genomic divergence between isolates,
as we observed in our data. Furthermore, if this strain is
significantly divergent from vaccine strains (which is also
shown in our data/Figures), it may be capable of vaccine
escape which is supported by our data from vaccinated
dogs and our serum neutralization testing. The exact
mechanism of vaccine protection in dogs with respect to
CDV is unknown. Therefore we do not know what mu-
tations, or combination of mutations, give rise to vaccine
escape and host adaptation for this strain. However, if it
is well-adapted in wildlife, it follows that infection in
Fig. 4 Alternate start sites for fusion (F) gene. The new strain (top two sequences) has a predicted start site 75 bp preceding that for America-2 A75/17
and Onderstepoort and 27 bp from Asia-2. This adds 25 and 9 amino acids, respectively, to the signal peptide region of the protein
Fig. 5 Serum neutralization assay. Five adult research dogs were
vaccinated with a modified live virus vaccine approximately 1 year
after vaccination with the same vaccine. CDV titers were determined
by serum neutralization using either the new strain or the vaccine
strain (Nobi). Viruses were each used at 100 TCID50 per well and the
results are reported as the means of three replicates. The experiments
were repeated, and the results for both experiments are included. The
titers were not significantly different between pre-vaccination and
post-vaccination when evaluating titers with the new strain. There was
a significant difference between pre- and post-vaccination titers when
testing with the vaccine strain, suggesting the memory response was
specific for the vaccine virus
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domestic dogs would be inefficient and/or infrequent.
Why exactly this strain is only recently causing disease
in dogs if it has been in wildlife long enough to become
a reservoir is unknown; it may have been around prior
to our discoveries yet undetected due to lack of genetic
evaluation of strains. However, the lack of diversity in a
hypervariable region from multiple dogs suggests this is
a newly introduced strain.
We believe the stable host reservoir is likely the endemic
wildlife population. The virus is highly labile outside of
the host, so cross-species transmission occasionally oc-
curs, thus the virus could be maintained in wildlife popu-
lations between outbreaks [20]. We have detected this
strain in raccoons and foxes, as well as three dogs with a
history of recent direct raccoon exposure. Raccoons,
which are among the most common wildlife species found
in cities and towns, are considered a secondary reservoir
of CDV and spillover of infection from domestic dogs with
spillback from raccoons is well documented [1].
While there have recently been multiple reports of new
genotypes/lineages, questions remain as to whether the
genetic differences represent significant differences in anti-
genicity. It has been suggested that changes in the glycan
shield may result in vaccine escape mechanisms. However,
comparative neutralization studies have shown that fully
glycosylated and de-glycosylated wild-type viruses are neu-
tralized with equal efficiency [21]. It was also demonstrated
that only 5 of the N-glycosylation sites (N149, N391, N422,
N456, and N587) are actually used by the virus and this gly-
cosylation pattern has been highly conserved in wild-type
strains. This argues against a glycan shield escape mechan-
ism for CDV, and the presence of N309 detected in this
new strain and in other recent wild-type strains, as well as
N584 in some Asian strains, is meaningless [21].
CDV is currently recognized as a single serotype [22].
However, preliminary evaluation of neutralization titers
comparing this strain to one of the America 1 type
vaccine strains showed significant differences (Fig. 5).
Neutralizing antibodies are often used as a substitute
marker for protection [23], with a neutralization titer of ≥
32 generally considered protective [24]. Evaluation of the
titers from this study, in light of this cut-off value, suggests
all 5 dogs would not have been considered protected pre-
booster, and one dog would not have been considered pro-
tected post-vaccination when evaluating neutralization ti-
ters with this new strain. All the dogs would have been
considered to have a protective titer both pre- and post-
vaccination when evaluating the antibody response with
the Onderstepoort vaccine strain. These results should be
considered from a diagnostic standpoint with regard to
which virus strain or strains should be used for routine
serum neutralization testing for dogs.
The extent to which antigenic variation is leading to
vaccine failure is unknown. This new strain has been
associated with disease in 3 properly vaccinated adult
dogs. All three dogs were euthanized due to severe
clinical disease. Two of the dogs were necropsied and
histologic findings were consistent with CDV infection.
Unfortunately, sera from these dogs were not available
for antibody testing. While it is possible these dogs were
vaccine non-responders, it would not be expected based
on the percentage of these animals seen in the general
population (approximately 1/5000 dogs, http://www.wsa
va.org/sites/default/files/WSAVA_OwnerGuidelines_Sep
tember2010.pdf ), and the fact that these dogs were all
different breeds and unrelated.
Cell-mediated immunity must also be considered with
regard to vaccine protection. This was not evaluated in
this study, but presence of a neutralizing titer correlates
with the presence of a T-cell response, though they are
not well correlated quantitatively [23]. A protective
cellular immunity can be present in the absence of a
detectable antibody-mediated response. A strong cellular
immunity causes viral elimination but a delayed or ab-
sent lymphocyte-mediated response results in viral per-
sistence in the CNS [25]. Challenge studies with this
new strain would best determine whether dogs are pro-
tected from the new strain via cross-protection or if the
new strain is genetically distinct enough to evade the
vaccine but that was beyond the scope of this project.
Critical CDV-specific herd immunity resulting from
low vaccination rates may contribute to outbreaks [22].
Vaccine histories were unknown for some of these
animals, but the majority of the cases were in dogs with
incomplete vaccination or no vaccination. This suggests
herd immunity is low due to reduced vaccination rates.
This has likely contributed to the emergence of this new
strain. Whether there is also reduced protection in vac-
cinated dogs as a result of extended vaccination intervals
is unknown. The issue of duration of protective immun-
ity maintained by booster vaccination every 3 years for
CDV may have to be reevaluated in light of the emer-
gence of new variants of CDV [5]. The veterinary pro-
fession should weigh the risks of side-effects due to
over-vaccination against the risk of a decreased herd
immunity with the re-emergence of epidemics as a con-
sequence [26]. Maintenance of high vaccination rates
using efficacious vaccines that induce a solid, resilient
immunity must still be given the highest priority in
control of distemper [22]. Our data suggests that
ongoing surveillance should be conducted to detect
and analyze new and emerging strains of CDV that may
facilitate vaccine evasion.
Conclusion
There is a newly detected lineage of CDV circulating in
the Southeastern portion of the United States. It is
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genetically distinct from all previously identified geno-
types, yet highly conserved within its own lineage. Contin-
ued and broadened surveillance, including wildlife, will
determine the impact of this genotype in comparison to
other circulating genotypes. While there have been
vaccine breaks associated with this genotype, vaccination
remains the best way to manage CDV in the absence of a
specific treatment for this virus.
Methods
Samples were submitted between 2010 and 2014 to the
UTCVM Clinical Virology Lab for canine distemper virus
detection. Submissions were mainly canine from eastern
Tennessee, but samples from Canada, Texas, Washington,
Kentucky, West Virginia, Virginia, and South Carolina
were also tested. Samples were also submitted for wildlife
including raccoons and foxes from Tennessee.
RNA was extracted from clinical samples (including
nasopharyngeal/conjunctival swabs, urine, and tissues) and
cell culture supernatant containing virus with a commer-
cially available extraction kit (QIAamp Viral RNA Mini
Kit, Qiagen, Valencia, CA, USA) as previously described
[7]. RNA previously extracted was stored at −80 °C.
Samples were tested for CDV by real-time RT-PCR.
cDNA from positive samples were genotyped by sequen-
cing the variable M-F intergenic region, and a phylogenetic
tree was constructed according to previously described
methods [7].
Samples used for genome sequencing included CDV
sample number 13–1941, which was isolated from lung
that had been stored at −80 °C from a fox that displayed
neurologic signs prior to euthanasia and tested negative
for Rabies virus. It was submitted to the pathology de-
partment for disposal from the Avian and Zoological
Medicine service in the UTCVM. The virus was cultured
on Vero SLAM cells (kindly provided by Dr. Edward
Dubovi, Cornell University, NY, USA). CDV sample
number 13–2262 was collected via urine from a 6 month
old puppy from South Carolina with clinical signs
consistent with canine distemper, and the sample had a
real-time RT-PCR Ct value of 13.11. This strain was not
isolated and whole RNA from the urine sample was used
directly for genome amplification.
Approximately 50 bp overlapping primer sets with
~1000 bp products were designed using Primer 3 [27, 28]
to amplify complete CDV genome sequence (minus the
extreme 5’ and 3’ non-coding ends) (Table 2). Two μL of
RNA per sample were run in 25 μL total volume reactions
using a commercially available master mix (SuperScript III
Platinum One-Step RT-PCR kit, Invitrogen, Life Tech-
nologies, Grand Island, NY, USA) using 300 nM of each
primer and one unit of RNAse inhibitor (RNAse Out,
Invitrogen, Life Technologies, Grand Island, NY, USA) for
RT-PCR. Samples were amplified in a thermal cycler
(GenePro, BIOER Technology, China) with a RT step at
50 °C for 30 min., activation step for the hot start Taq
polymerase at 94 °C for 2 min., followed by 35 cycles of
denaturation at 94 °C for 30 s., annealing at 60 °C for
1 min., and elongation at 72 °C for 3 min., with an add-
itional elongation step at 72 °C for 10 min. The RT-PCR
products were electrophoresed on a 1 % TBE agarose
gel stained with SYBR Safe®, and visualized by SYBR©
Green-filtered UV light with a CCD camera system
(UVP, Inc., Upland, CA, USA). Products with a single
Table 2 Primer sets for genome amplification
Set Forward Reverse Nucleotide positiona
F1/R1 GAGAACAAGGTCAGGGTTCAG TTGCCGGCAGATCTTCTAAC 77–1231
F2/R2 TGCTATGGGAGTTGGTGTTG TCTTCGCCAGAATCCTCAGT 1112–2273
F3/R3 CGAAGATGCTGACAGTCTCG GAAAGCAGTTCTGTGCCTGTT 2169–3368
F4/R4 CAAAGTCACAAACACAACATGC GGGACTGATGGTTGCAAGAC 3223–4372
F5/R5 TGTTACCCGCTCATGGAGAT CCAAGTACTGGTGACTGGGTCT 4272–5433
F6/R6 GGTGCATTGGAATAGCCAGT GCAGGTATCGGAGGCAATAA 5299–6530
F7/R7 CTTGGTGTCTGGGACGATG GCTGCCGATGCAATAGATTT 6377–7578
F8/R8 GGTTACGGTTGCCACAAAAA TCCATAATCTGGGATGTTTGAA 7389–8580
F9/R9 AAGAACGGAACAGTCCTTGG TTGTGACTGGTGAGGTCAATG 8441–9685
F10/R10 TGCAAAGCTCACAGTGGTTC CAGGCTCGCATTTTGTAGGT 9496–10696
F11/R11 GAGGACTCTCAGTTTGACCCTTA CACATCCCGTGTCATAGCTG 10539–11777
F12/R12 CCGCATGCAGTAACATTTCA GCCCATGAGTACACAGTTGCT 11626–12772
F13/R13 TACATCGGGTCCACAACAGA CCTCATCACTTTCGCACAAA 12663–13821
F14/R14 CACGGACCCTCTCTTGACTC CGAGGTAGGCCTCTGTTGAC 13683–14901
F15/R15 GCGACTGGGTTCAAGGATTTA AGCAATGAATAGCAGAGGGTTAG 14797–15623
aReference genome AF164967 (A75/17)
Riley and Wilkes Virology Journal  (2015) 12:219 Page 8 of 10
band were purified using ExoSAP IT (Affymetrix,
Santa Clara, CA, USA). Products with more than one
band but a single clear product at ~1000 bp (3/15 sets)
were excised and gel purified (QIAquick gel extraction kit,
Qiagen, Valencia, CA, USA) and all products were capil-
lary sequenced at the UT Molecular Biology Core Facility
using the same primers used for the PCR reactions.
Chromatograms for capillary DNA sequence were
manually edited and assembled using Geneious©, and all
positions in the sequence had at least 2x coverage. Avail-
able reference genomes and H genes representing the
major CDV lineages were downloaded from GenBank and
aligned to CDV 13–1941 and CDV 13–2262 using MAFFT
v7.017 [29]. Nucleotide substitution model GTR was se-
lected using ModelGenerator v0.85 [30] and phylogenetic
trees were constructed using MRBAYES v2.0.9 (genomes)
[31] with 1,000,000 iterations with subsampling every 1000
trees and a burnin of 20,000 iterations [32] or Neighbor-
Joining method (H gene). Individual coding sequences
(CDS) were predicted using GLIMMER3 v1.4 [33], ex-
tracted, translated and aligned to representative sequences
from GenBank. Phylogenetic trees for individual protein
sequences were generated using UPGMA in Geneious©
Tree Builder (version 6.1.4, Biomatters http://www.ge
neious.com) with the Jukes-Cantor distance model.
For evaluation of antigenicity, blood was collected from
5 adult dogs that are part of the UTCVM teaching colony,
according to Institutional Animal Care and Use Commit-
tee guidelines (University of Tennessee Knoxville IACUC
protocol 1954). Samples were collected from the animals
just prior to receiving a Nobivac vaccine (Merck Animal
Health, Summit, NJ, USA) and again 5 days following
vaccination. Each dog had been given the same vaccine
approximately 1 year prior. Serum was separated from the
cells and stored at −20 °C. Neutralization titers were de-
termined by a standard procedure [34] using 100 TCID50
per well of the fox isolate (13–1941) or Nobivac isolate.
The Nobivac isolate was prepared in the same manner as
described for the fox isolate. Samples were run in triplicate
and each test was duplicated to evaluate reproducibility. A
Mixed ANOVA method (SPSS Software, SPSS Inc, Chi-
cago, IL, USA) was used to compare serum neutralization
titers between the viruses and the two time points. In
order to determine which pairs of means were signifi-
cantly different, mean separation tests were run using the
Tukey-Kramer method at a significance level of p = 0.05.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
MCR and RPW designed the study and carried out the molecular testing.
RPW performed the serum neutralization studies and MCR performed the
phylogenetic analyses. Both authors contributed to the writing of the
manuscript and both authors read and approved the final manuscript.
Acknowledgements
We would like to thank Ann Reed at the University of Tennessee Office of
Research Computing Support for the statistical analysis of the data. We would
also like to thank Elena Sanchez and Sarah Elliott for their technical assistance.
Disclaimer
The findings and opinions expressed herein belong to the authors and do
not necessarily reflect the official views of the United States Army or the
Department of Defense.
Funding
This work was supported by the Department of Biomedical and Diagnostic
Sciences Education Advancement and Research Fund, College of Veterinary
Medicine, The University of Tennessee.
Author details
1Department of Biomedical and Diagnostic Sciences, College of Veterinary
Medicine, The University of Tennessee, 2407 River Drive, 37996 Knoxville, TN,
USA. 2United States Army, Medical Service Corps, USA. 3Present address:
Veterinary Diagnostic and Investigational Laboratory, College of Veterinary
Medicine, The University of Georgia, 43 Brighton Road, 31793 Tifton, GA,
USA.
Received: 11 September 2015 Accepted: 1 December 2015
References
1. Kapil S, Yeary TJ. Canine distemper spillover in domestic dogs from urban
wildlife. Vet Clin Small Anim. 2011;4:1069–86. 10.1016/j.cvsm.2011.08.005.
2. Budaszewskia Rda F, Pinto LD, Weber MN, Caldart ET, Alves CD, Martella V,
et al. Genotyping of canine distemper virus strains circulating in Brazil from
2008 to 2012. Virus Res. 2014;180:76–83. doi:10.1016/j.virusres.2013.12.024.
3. Espinal MA, Díaz FJ, Ruiz-Saenz J. Phylogenetic evidence of a new canine
distemper virus lineage among domestic dogs in Colombia. South America
Vet Microbiol. 2014;172:168–76. doi:10.1016/j.vetmic.2014.05.019.
4. Gamiz C, Martella V, Ulloa R, Fajardo R, Quijano-Hernandez I, Martinez S.
Identification of a new genotype of canine distemper virus circulating in
America. Vet Res Commun. 2011;35:381–90. doi:10.1007/s11259-011-9486-6.
5. Kapil S, Allison RW, Johnston III L, Murray BL, Holland S, Meinkoth J, et al.
Canine distemper virus strains circulating among North American Dogs. Clin
Vaccine Immunol. 2008;15:707–12. doi:10.1128/CVI.00005-08.
6. Sultan S, Charoenvisal N, Lan NT, Yamaguchi R, Maeda K, Kai K. The Asia 2
specific signal peptide region and other domains in fusion protein genes
characterized Asia 1 and Asia 2 canine distemper viruses. Virol J. 2009;6:157.
doi:10.1186/1743-422X-6-157.
7. Wilkes RP, Sanchez E, Riley MC, Kennedy MA. Real-time reverse transcription
polymerase chain reaction method for detection of canine distemper virus
modified live vaccine shedding for differentiation from infection with
wild-type strains. J Vet Diag Invest. 2014;26:27–34. doi:10.1177/
1040638713517232.8.
8. Demeter Z, Palade EA, Hornyak A, Rusvai M. Controversial results of the
genetic analysis of a canine distemper vaccine strain. Vet Microbiol. 2010;
142:420–6. doi:10.1016/j.vetmic.2009.10.017.
9. Martella V, Blixenkrone-Møller M, Elia G, Lucente MS, Cirone F, Decaro N,
et al. Lights and shades on an historical vaccine canine distemper virus,the
Rockborn strain. Vaccine. 2011;29:1222–7. doi:10.1016/j.vaccine.2010.12.001.
10. Blixenkrone-Møller M, Svansson V, Have P, Orvell C, Appel M, Pedersen IR,
et al. Studies on manifestations of canine distemper virus infection in an
urban dog population. Vet Microbiol. 1993;37:163–73.
11. Lan NT, Yamaguchi R, Inomata A, Furuya Y, Uchida K, Sugano S, et al.
Comparative analyses of canine distemper viral isolates from clinical cases
of canine distemper in vaccinated dogs. Vet Microbiol. 2006;115:32–42.
12. Simon-Martı´nez J, Ulloa-Arvizu R, Soriano VE, Fajardo R. Identification of a
genetic strain of canine distemper virus from clinical cases in two vaccinated
dogs in Mexico. Vet J. 2008;175:423–6.
13. Calderon MG, Remorini P, Periolo O, Iglesias M, Mattion N, La Torre J.
Detection by RT-PCR and genetic characterization of canine distemper virus
from vaccinated and non-vaccinated dogs in Argentina. Vet Microbiol.
2007;125:341–9.
Riley and Wilkes Virology Journal  (2015) 12:219 Page 9 of 10
14. Mochizuki M, Hashimoto M, Hagiwara S, Yoshida Y, Ishiguro S. Genotypes of
canine distemper virus determined by analysis of the hemagglutinin genes
of recent isolates from dogs in Japan. J Clin Microbiol. 1999;37:2936–42.
15. Lednicky JA, Dubach J, Kinsel MJ, Meehan TP, Bocchetta M, Hungerford LL,
et al. Genetically distant American Canine distemper virus lineages have
recently caused epizootics with somewhat different characteristics in
raccoons living around a large suburban zoo in the USA. Virol J. 2004;1:2.
doi:10.1186/1743-422X-1-2.
16. Pardo IDR, Johnson GC, Kleiboeker SB. Phylogenetic characterization of canine
distemper viruses detected in naturally infected dogs in North America. J Clin
Microbiol. 2005;43:5009–17.
17. Keller SM, Gabriel M, Terio KA, Dubovi EJ, VanWormer E, Sweitzer R, et al.
Canine distemper in an isolated population of fishers (Martes pennanti)
from California. J Wildl Dis. 2010;48:1035–41. doi:10.7589/2011-12-350.
18. von Messling V, Cattaneo R. Amino-terminal precursor sequence modulates
canine distemper virus fusion protein function. J Virol. 2002;76:4172–80.
19. Anderson DE, von Messling V. Region between the canine distemper virus
M and F genes modulates virulence by controlling fusion protein
expression. J Virol. 2008;82:10510–8.
20. Trebbien R, Chriel M, Struve T, Hjulsager CK, Larsen G, Larsen LE.
Wildlife reservoirs of canine distemper virus resulted in a major
outbreak in Danish farmed mink (Neovison vison). PLoS ONE. 2014;
DOI:10.1371/journal.pone.0085598.
21. Sawatsky B, von Messling V. Canine distemper viruses expressing a
hemagglutinin without N-glycans lose virulence but retain immunosuppression.
J Virol. 2010;84:2753–61.
22. Harder TC, Osterhaus ADME. Canine distemper virus- a morbillivirus in
search of new hosts? Trends in Microbiol. 1997;5:120–4.
23. Perrone D, Bender S, Niewiesk S. A comparison of the immune responses of
dogs exposed to canine distemper virus (CDV) — differences between
vaccinated and wild-type virus exposed dogs. Can J Vet Res. 2010;74:214–7.
24. Gray LK, Crawford PC, Levy JK, Dubovi EJ. Comparison of two assays for
detection of antibodies against canine parvovirus and canine distemper
virus in dogs admitted to a Florida animal shelter. J Am Vet Med Assoc.
2012;240:1084–7.
25. Beineke A, Puff C, Seehusen F, Baumgartner W. Pathogenesis and
immunopathology of systemic and nervous canine distemper. Vet Immunol
Immunopathol. 2009;127:1–18.
26. Horzinek MC. Vaccine use and disease prevalence in dogs and cats. Vet
Microbiol. 2006;117:2–8.
27. Koressaar T, Remm M. Enhancements and modifications of primer design
program Primer3. Bioinformatics. 2007;23:1289–91.
28. Untergrasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC. Remm, et al.
Primer3 - new capabilities and interfaces. Nucleic Acids Res. 2012;40:e115.
29. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid
multiple sequence alignment based on fast Fourier transform. Nucleic Acids
Res. 2002;30:3059–66.
30. Keane TM, Creevey CJ, Pentony MM, Naughton TJ, McInerney JO.
Assessmentof methods for amino acid matrix selection and their use on
empirical data shows that ad hoc assumptions for choice of matrix are not
justified. BMC Evol Biol. 2006;6:29–45.
31. Huelsenbeck JP, Ronquist F. MRBAYES: Bayesian inference of phylogenetic
trees. Bioinformatics. 2001;17:754–5.
32. McCarthy AJ, Goodman SJ. Reassessing conflicting evolutionary histories of
the Paramyxoviridae and the origins of respiroviruses with Bayesian
multigene phylogenies. Infect Genet Evol. 2010;10:97–107. doi:10.1016/j.
meegid.2009.11.002.
33. Salzberg SL, Delcher AL, Kasif S, White O. Microbial gene identification using
interpolated Markov models. Nucleic Acids Res. 1998;26:544–8.
34. Burleson I, Chambers TM, Wiedbrauk DL. Encephalomyocarditis virus
neutralization. In: Virology a laboratory manual. San Diego: Academic;
1992. p. 125–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Riley and Wilkes Virology Journal  (2015) 12:219 Page 10 of 10
